Bioelectronics Corp (BIEL)

[3331]

BIEL OPTIMIZING THE NETFLIX BUSINESS MODEL!
Netflix has increased over 325,000%, from .35 (on 10/9/02) to about $1,150 today!
1) Product price is about the same and Actipatch lasts as long as a monthly Netflix subscription (much longer when the on/off switch is utilized).
2) Actipatch/RecoveryRX has much larger market potential. While both are available to virtually every human on the planet, RecoveryRX Veterinary is also available to their pets! Also, the high margin RecoveryRX is available by prescription, and the "wellness market" is available for the aches and pains not covered by FDA clearances (menstrual, migraine, restless leg, depression, etc. - simply attach it over the vagus nerve!).
3) BIEL's product profit margins are much higher as their operating costs are virtually nothing compared to Netflix (no movie studios and actors required to constantly put out new content).

In advance of the usual illiterate responses such as "you need to enroll in a couple of basic business courses at your local community college" and "if you don't know, I'm not going to explain it", I'll repeat my offer to meet with the basher/whiner/ambulance chasers to compare college degrees and professional work experience. I suspect the Mayflower mover/insurance office staffer with the AutoCAD (2-day training) certificate would be the most educated - although he appears to have a problem understanding English (ESL?) and lately is on a DELIRIOUS rampage attacking his basher followers as stupid idiots. It would be so interesting to meet the people who devote their lives to bashing a small company trying to achieve the American Dream. Who does that?

ACTIPATCH WILL BE A "STANDARD OF CARE" PRODUCT!
With FDA clearance for treatment of knee, back, wrist, hips, ankles, plantar fasciitis and all musculoskeletal pain, how can it not, especially at the low price of $35 - with a much longer battery life (720 hours or several months if extended with the on/off button) than the competition! The Actipatch FDA clearance allows it to be sold over the counter (without a prescription). The RecoveryRX applications (post operative pain, edema, wound care, etc.) do require a doctor order. Add in RecoveryRx-Veterinary and you have over 10 billion potential repeat customers - every adult and pet on the planet (every month). Then there is the "wellness" market, as many people use Actipatch for Restless Leg Syndrome (RLS is estimated to affect 10% of adults worldwide), menstrual pain, migraines and other "off label" aches and pains.

RECOVERYRX-VETERINARY COULD/SHOULD BE A GOLDMINE!
The Assisi Loop sells over 300/month just on Amazon @ $329, with 1/20 the battery life. Assisi Loop customers are paying the equivalent of over $6,000 when you factor in the additional cost and lower battery life, but Assisi customers seem happy to pay it based on the numerous 5-star reviews. RecoveryRx/Veterinary should be sold as a two/pack - one applied on the vagus nerve and the other attached on the area of pain.

SOON
BIEL's easiest, fastest and most likely path to success is to generate a $400k revenue quarter and/or a $1.5 million revenue year (or if management hints Q1 2025 was profitable, or Q2 will be). A $400k revenue quarter would achieve cash flow positive/profitability and increase the pps to copper, which would solve most of BIEL's problems and open up a world of opportunities for the company.

The analyses provided below demonstrate the connection between revenues, profitability and the pps using standard analysis methods. Even if only 10% of the "catalysts" identified below materialize, the pps will still hit copper. This would generate a huge amount of free publicity in the financial and news media (an example of capitalism at it's finest - achieving the American Dream!), which would then lead to an exponential increase in product sales. With BIEL's low operating costs and business model, BIEL could pay off their loans quickly and then use subsequent profits to implement an aggressive stock buyback program, which could rocket the pps to $1+!

BIEL COULD HIT COPPER IN THE "BLINK OF AN EYE"!
The first catalyst will likely be the announcement of a partner for the USA, which could come any day. The key statement from the annual report is "The Company has focused attention on seeking a distribution and licensing partner for the OTC US market". If investors value this partnership at $300k (and add it to the $496k of mostly international revenue reported for 2024), the pps gets out of the trips. If the investor valuation is $1 million, then the pps hits COPPER! The last time this happened (KT deal in 2021), BIEL soared 1,600%.

BIEL IS SIMPLE TO ANALYZE!
Q3 2021 was BIEL's only profitable quarter ($22,381) with $414,700 revenue (including $100k+ in covid relief funds). PROFITABILITY IS VERY CLOSE! Seems like $1.5 million annual revenue (or a $400k quarter) should do it, due to BIEL's extremely low operating costs and business model. Then the corresponding pps should hit .01 - and increase .01 for each additional $2.5 million annual revenue (P/E = 100). The $40 million tax-loss carry forward will make the first $40 million in profits tax free and accelerate the path to profitability. KISS - KEEP IT SIMPLE STUPID! 💋

PROSPECTUS
BIEL's low-cost OEM business model has put the company in position to be profitable soon such that if investors project for 2025:
1) annual revenue of $800k - this will be a significant increase from the previous three years and get the pps out of the trips;
2) $1.5 million annual revenue (or a $400k quarter) - this will likely achieve cash flow positive/profitability and get the pps to copper.
3) BIEL's prospects for achieving a 1,000% to 10,000% increase in pps are better than any other company on the market right now!
4) The path to profitability will be accelerated by the tax-loss carryforward of about $40 million (no tax on first $40 million profit).
5) BIEL GOES VIRAL AT PPS = .006!
Market cap = $150 million at pps = .006, which would generate massive press (free marketing/advertising) in the news and financial media when they report that the pps increase is better than the gains in Amazon and Apple (3,000% over the past 10 years). It would solve all of BIEL's problems and create numerous opportunities for the company. The Reddit crowd would be all over it (generating massive free online marketing/advertising). If the company then declares profits would be used for a share buyback program (after paying off the loans), the pps would soar ($1+) and the rise would be sustained.
6) PPS = .02: 200,000% increase (equivalent to Apple, Amazon and Netflix from their low point). Requires $5 million profit (P/E = 100). Profits will be accelerated by the tax loss carryforward (no tax on first $40 million profit)!
7) PPS = .10: Requires $25 million profit (P/E = 100). Profits will be accelerated by the tax loss carryforward (no tax on first $40 million profit)!

❤️20 REASONS TO LOVE BIEL❤️
Note: Some of the following was actually provided by the #1 basher - a former Mayflower mover/insurance office staffer - who acknowledges BIEL is "very close to profitability every quarter":
1. It's a real company with real products.
2. The company is not burning $$$ millions every quarter trying to get a product through the FDA wringer. They've accomplished FDA clearance (5) already.
3. The company is very close to profitability every quarter. BIEL will likely be profitable soon, it not already (a $400K quarter should do it).
4. There is no toxic debt. The company is not sinking under death spiral financing.
5. Actipatch has thousands of excellent, mostly 5-star customer reviews.
6. The $40 million tax-loss carry forward will make the first $40 million in profits tax free and accelerate the path to profitability.
7. If $800k revenue is reported for 2024, it will likely gets the pps out of the trips.
8. Technical indicators (Golden Cross, Blue Sky Breakout, etc.) turning positive. Every bull run starts with this.
9. Bare bones expenses: about $750k/year for GENERAL AND ADMIN EXPENSES (salaries, utilities, R&D, Advertising, etc) with a burn rate of about $220k/year for Other Gen and Admin Expenses.
10. New utility patent (pending) for chronic pain inflammation (vagus nerve) - HUGE.
11. Actipatch will be a Standard of Care product.
12. They have 5 FDA clearances with more pending.
13. Insurance coverage is expanding - currently covered by the UK National Health Service (and Taiwan?).
14. Been in business for over 20 years and never reverse split.
15. Accepted for use by the Veterans Administration.
16. Rapidly expanding in the veterinary/pet market.
17. New contract/partner rumors swirling.
18. Amazon/Apple type of return on investment (ROI) very possible.
19. Fed forecast to cut interest rates five times this year, which greatly benefits OTC stocks like BIEL. The last time this happened (2021) BIEL surged 1,600%.
20. See 1 - 19!

Hope this Tik-Tok sensation is part of the BIEL Whelan family!
https://goss.ie/showbiz/spotlight-on-irish-ti...lan-303910

POTENTIAL
The potential is mind-boggling - especially if Actipatch is identified as a "wellness product" for the applications not currently covered by the FDA clearances. From the 2024 Annual Report:

BioElectronics is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Our innovative pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.

The chronic pain market is larger than diabetes, heart disease, and cancer combined, with 20% of adults globally suffering from chronic pain. ActiPatch addresses the unmet need for 1.5 billion worldwide chronic pain sufferers. The Company’s medical devices modulate the body’s nerve activity to dampen the pain perception, which reduces drug use. RecoveryRx will be an ideal choice in reducing postoperative pain and exposure to long-term effects of opioid/NSAID therapy.

The technology has the potential to become the standard of care throughout the healthcare continuum across the OTC and healthcare markets. BioElectronics’ technology offers significant opportunities in menstrual pain, heel pain, migraine headaches, diabetic neuropathy, postoperative surgery, chronic wounds, bone growth stimulation, and other applications.

In February 2020, BioElectronics obtained a new 510(k) clearance from the U.S. FDA, granting over-the-counter marketing clearance for the drug-free ActiPatch medical device, to cover all musculoskeletal pain complaints. This paves the way for new products to treat all medical claims for musculoskeletal pain, including in the back, knee, hips, wrists, elbow, and ankle.

DR. OZ
The Dr. Oz effect will be interesting, considering his recent appointment as Administrator of the Centers for Medicare and Medicaid Services. When Actipatch was featured on the Dr. Oz show, it achieved record sales and sold out the inventory.

BIEL GONNA RUN LIKE 2021!
Everything is falling into place just like 2021. A new distribution partner for the USA will be announced soon (replacing the KT deal from 2021). OTC bull market runs are fueled by the Fed cutting interest rates, and the Fed is now forecast to cut five times this year. Falling interest rates indicate a more accommodative money policy which makes investors more interested in the higher risk/higher reward stocks found on the OTC. The last time this happened, BIEL ran more than 1,600% to .0088. The previous BIEL runs coincided with similar OTC bull markets in 2017, 2014 and 2009.

The technical indicators come first - the Golden Cross and the Blue Sky Breakout. Then the fundamentals kick in (Taiwan, VA, Veterinary, New Zealand...). BIEL is a Reddit investors dream. Once they become aware of BIEL (via the financial press), the pps will rocket, product sales will soar, and we'll be celebrating like 2021! https://microcapdaily.com/exciting-week-for-bioelectronics-corp-otcpink-biel/124825/

Expect a 5,000% ROI (pps = .01 from .0002) when BIEL reports a profit - or if management hints Q1 (2025) was profitable. This would put BIEL amongst the all-time greatest stocks.
Gemini says "a 5,000% ROI is fantastic but very rare and typically associated with high-risk investments such as penny stocks or early-stage startups".
Copilot says: "achieving a 5,000% return on investment (ROI) is rare and typically involves high-risk stocks, often in emerging industries or during market booms. Some penny stocks, for example, have been highlighted for their potential to deliver such returns".

BIEL IS THE NEXT AMAZON/APPLE (in terms of ROI)!
When BIEL hits .006, the return on investment for a .0002 buy (for those of us fortunate enough to get them recently) will be about the same as the 10-year ROI (3,000%) for Amazon and Apple (stocks I sold too soon). Microsoft 10-year ROI is ONLY 900%. BIEL can hit .006 in IN THE BLINK OF AN EYE, as $1.5 annual revenue (or a $400k quarter) should do it (due to BIEL's extremely low operating costs and business model). There are many indications that this will be accomplished soon, if it hasn't been already! We know that Taiwan, the VA, South Africa and Bulgaria are in progress, as is RecoveryRx-Veterinary in Europe (with the USA pending). Canada is expanding, New Zealand sales started March 1 and hopefully Australia will soon follow.

BIEL is a Venture Capitalist Dream! The opportunity to get in on the "next big thing", but with a company that has been in business for over 20 years (rather than a start-up). BIEL is probably the closest that any of us will get to having a venture capital kind of opportunity.
1) BIEL products have Standard of Care pain management potential for every adult and pet on the planet.
2) BIEL has 5 FDA clearances (with more pending) and the products work extremely well (some say like a miracle).
3) Upside ROI is huge (>10,000%) with minimal downside risk!
4) BIEL should be able to use their China manufacturer to ship directly to their international distributors and Viant for their USA sales to avoid tariffs.

BIEL HITS COPPER WHEN THE FOLLOWING OCCURS!
pps > .001 after management drops some positive hints. The Golden Cross (already achieved) and Blue Sky Breakout will get the technicians/chartists/Reddit crowd attention and the pps out of the trips;
pps > .01 after management drops some positive hints that convinces investors that break even/cash flow positive (annual rev = $1.5 mil) will be achieved, combined with the momentum from a 2021 like OTC run (fueled by the Reddit crowd);
pps > .04 after pr indicates the annual revs from Taiwan (in progress) can be valued at $10 mil+;
pps > .08 after pr indicates the annual revs from the VA (in progress) can be valued at $10 mil+;
pps > .12 after pr indicates the annual revs from RecoveryRx Veterinary (pending) can be valued at $10 mil+;
pps > .16 after pr indicates the annual revs from new contracts (distributors, partners, New Zealand, etc.) can be valued at $10 mil+;
Above pps values are based on P/E = 100
For P/E = 200, pps = .32
For P/E = 300, pps = .48
pps > $1 after loans are paid off and a stock buyback is initiated.

CATALYSTS (Details):
1) USA distribution partner announcement.
2) Taiwan - there are over 80 public hospitals and over 400 private hospitals in Taiwan. They have national health insurance and are rated the world's number one health system.
Assume 100 Taiwan hospitals order 100 Actipatch/RecoveryRx per month @$100 each for BIEL:
$100 x 100 hospitals x 100 x 12 mo = $12,000,000 rev/year.
Using profit = $10 mil and P/E = 100: PPS = .04.
Note: RecoveryRx Veterinary also appears to be in play in Taiwan.
3) 1000 Veterinarian Clinics (USA):
Conservatively assume each office orders 10/mo. @ $100 each for BIEL (Vet sells for $200, a bargain compared to Assisi):
1000 x 100 x 10 x 12 = $12,000,000 rev/year.
Note: RecoveryRx Veterinary also appears to be in play internationally.
4) Veterans Administration: There are over 1,000 VA facilities in the U.S. Conservatively assuming 100 VA hospitals order 100 RecoveryRx per month ($100 each for BIEL):
100 x 100 x 100 x 12 = $12,000,000 rev/year.

Sub-total for VA + VET = Using $20 mil (profit) and P/E = 100: PPS = .08!
TOTAL (Taiwan + VA + Veterinary + applying the tax loss carryforward):
pps = .12 (P/E = 100)
pps = .24 (P/E = 200)
pps = .36 (P/E = 300)
Additional revenue could be generated from new FDA clearances, vagus nerve patent, NPA, UK/Australia contract rumor, RecoveryRx Veterinary international sales, New Zealand, etc. Initiating a stock buyback program after all of the loans are paid off would propel the pps much higher (pps = $1).

BIEL FACT CHECK:
1) The basher/ambulance chasers repeatedly complain about the nearly 25 billion shares outstanding, but they can't provide a single reason why. It's irrelevant as it is accounted for in the VALUATION (pps) - 25 billion shares @.0002 = $5 million is the same valuation as 1 million shares at $5/share. NVIDIA has the same number of shares outstanding as BIEL, Apple and Amazon will soon have billions more (after the next split), and nobody is concerned! The stock market is all about valuation (outstanding shares x pps) - you buy if you think a stock is under-valued and sell if you think it is over-valued. Only amateurs/newbies/bashers do not understand this simple concept. Right now, investors feel BIEL is fairly valued between $2.5 - 5 million, but if news develops where investors feel $1 billion is fair value, you will see the BIEL pps rise accordingly (pps = .04). Some have tried to dispute this by changing the subject to dilution. BIEL has not diluted significantly in many years, and there is no indication it will in the future. The low pps is actually an advantage at this point, as it makes BIEL affordable to any investor (big and small). If you have $1,400 to invest, would you rather own 7 million shares of BIEL or 1 share of O'Reilly Auto Parts? The Reddit crowd would definitely choose BIEL.

2) BIEL's valuation is currently $5 million (for revs of $715k last year), which is undervalued compared to stocks (like SERV and QUBT for example) with billion-dollar valuations but only half of BIEL's revenue. When people become aware of the benefits of PSWT/PEMF and the huge multi-billion-dollar drug free pain management market - that desperately needs FDA cleared Actipatch/RecoveryRx/RecoveryRx Veterinary- BIEL will SOAR!

3) BIEL has been in business for over 20-years and has NEVER done a reverse split, which is VERY IMPRESSIVE!

4) Supply/Demand - the majority of the outstanding shares are in tight hands, so the pps will move up like a rocket after ignition, as the supply of available shares will be less than the demand (SQUEEZE!). Shareholders can help fuel the blast off by locking up their shares with "good until cancelled sell orders" (@$1) so their shares cannot be borrowed by the short sellers, thereby further reducing the supply.

BUYOUT
Right now, I doubt anything under $50 million would be considered (accounting for loans, etc.). That's out of my range, but in the future - after the pps increases, loans are paid off and a share buyback is implemented - I could see a point where a group of shareholders could get together and leverage their shareholdings to make an offer. Years ago, Simpsonly and some other shareholders made an offer to Andy but were turned down. Not sure if Orel Hershiser was part of that group, but he is rumored to be a shareholder and a big fan of the products (would be a great influencer for BIEL).

LICENCE/PARTNER/MERGER?
The Signal Relief Patch (in business for a little over a year) costs about twice as much as the Actipatch, but is much less effective at reducing pain and will probably never gain FDA approval. However, they do have lots of money for marketing and advertising - their ads are on national TV every day, along with on-line media. They might be a good partner for Actipatch - we could use their advertising/marketing budget, and they could use Actipatch (integrated with their patch) to make their device more effective at reducing pain. It could work the way the KT licence was supposed to. Signal Patch is private now, so a merger with BIEL would give them quick access (compared to an IPO) to the stock market, where their venture capitalists would get a better return on their investment (than stay private).

IS BIEL THE NEXT MSFT?
Those that bought one share of Microsoft at the IPO price of $21 saw their investment increase to $210,000 recently (10,000 X). Someone buying 1 million shares of BIEL @.0002 would see their $200 investment grow to $2,000,000 (pps = $2) with equivalent growth. Is this possible? Absolutely, after BIEL becomes profitable, pays off their loans and then implements an aggressive stock buyback program!

SUPPLEMENT (courtesy of beacham)
I think what is happening is BIEL has ‘a deal’ w/ one of the suppliers/distributors to CMMS and/or the VA. I also think we have an emerging contract relationship w/ Viant and that is the reason Dr. Sree Koneru is on our BOD.

These presumptions (opinions) solve a lot in terms of logistics and financials. For manufacturing, it removes the uncertainty of a China-based supplier of product. Taiwan is a flashpoint and relations w/ China are strained. Viant has international reach that can supply product to any of our distributors worldwide w/o all the drama and tension, not to mention shipping time, of having a manufacturer thousands of miles away in a potentially hostile situation. How this ties into the paucity of Raw Materials expenditures over the last 4 yrs is a good question. We keep CICD for the Asian distribution but should circumstances change, we have Viant. They also have a Design & Development division. It’s a smart move.

Working w/ a ‘local’ supplier to CMMS and/or the VA takes the buyout scenario off the table for now. It does, however, give BIEL some certainty in terms of revenue and, if/when announced, would do wonders for the share price.

The logistics of this are complicated, complex, time sensitive and politically charged, involving not only the nuts and bolts but official approvals as well. I think the Atlanta sites are a pilot project / launch-point to work out the myriad details. Working through a supplier who has already done the paperwork to work w/in the CMMS and/or VA bureaucracies is a huge bonus. They would ‘simply’ add our products to their catalog. Doing the legwork to make that happen would be their responsibility and thus freeing us to focus on supplying product to them for their distribution to the numerous CMMS and/or VA locations.

It would also explain having an NDA and the near total silence that ensues. Nobody needs or wants an army of bashturds crawling up your backside agitating for the impossible. The scope and magnitude of this project is enormous, beyond words. CEO Kelly Whelan has not been given enough credit, in my opinion. And all of this work must be done under the radar, by legal necessity, as per an NDA. Lots of moving parts and endless details. When CEO Kelly says they are working, I believe her.

3331 is restricted to one post per day, which is often deleted.